Xylem price target lowered to $165 from $170 at Oppenheimer

Oppenheimer lowered the firm’s price target on Xylem (XYL) to $165 from $170 and keeps an Outperform rating on the shares. The firm notes shares have fallen about 10% since Xylem reported Q4 results. Although Xylem’s Q4 print was solid, the team’s Q1 2026 and full-year guidance fell modestly short of consensus estimates – directionally “feeding into” the bear thesis of peaking demand and funding risk, Oppenheimer adds.